In particular, total CD4+ T cell numbers increased concomitantly with a major shift in Ki67+ GrzB+ effector CD4+ T cells and reduced T reg cells (Figs. 6B and EV5A), consistent with an increase in activated CD4+ T cells in spleens of breast cancer-bearing mice following eribulin treatment (Takahashi-Ruiz et al, 2022). The gene discussed is CD4; the disease is breast carcinoma.